Johnson & Johnson Completes Purchase Of Israeli Startup V-Wave

American pharmaceutical giant Johnson & Johnson has completed its purchase of Israeli medtech company V-Wave, which makes a device to treat heart failure, after the prospective acquisition was announced in August. 

The Israeli company has now become part of Johnson & Johnson MedTech.  

V-Wave’s proprietary, minimally invasive Ventura Interatrial Shunt (IAS) is designed to treat patients with heart failure. The shunt between the left and right atria in the heart aims to reduce elevated pressure in the left atrium. 

It received FDA Breakthrough Device Designation in 2019 and CE mark in 2020, and, according to Johnson & Johnson, has the potential to be the first device of its kind to market.

The American multinational said in August that it would pay up to $1.7 billion for V-Wave. This included a sum of $600 million upfront, followed by further payments totalling some $1.1 billion should V-Wave hit certain regulatory and commercial milestones. 

“We’re excited to officially welcome V-Wave to Johnson & Johnson MedTech,” saif Johnson & Johnson Executive VP and Worldwide Chairman Tim Schmid. 

“V-Wave’s novel implantable device, the Ventura Interatrial Shunt, offers tremendous promise for patients experiencing heart failure with reduced ejection fraction. This technology has the potential to be the first device of its kind to market. We look forward to working with the talented V-Wave team to bring this transformative innovation to patients.”